Business

UK authorises Moderna’s Covid-19 vaccine for children as young as 12

Brittain’s decision not to roll out vaccines to healthy children over 12 was based partly on some rare side effects seen particularly in male teenagers

Britain’s drug regulator authorised Moderna ’s Covid-19 shot for children as young as 12, though few are likely to receive it in the near term as the country remains an outlier in its policy on vaccinating children.
Britain’s drug regulator authorised Moderna ’s Covid-19 shot for children as young as 12, though few are likely to receive it in the near term as the country remains an outlier in its policy on vaccinating children.
Tue Aug 17 2021 - 17:10

Britain's drug regulator authorised Moderna 's Covid-19 shot for children as young as 12, though few are likely to receive it in the near term as the country remains an outlier in its policy on vaccinating children.

The UK’s Medicines and Healthcare products Regulatory Agency extended the existing conditional marketing authorisation for the Spikevax shot to 12- to 17-year-olds, the regulator said in a statement on Tuesday.

It is up to the government’s advisory committee – the Joint Committee on Vaccination and Immunisation – to decide if and when the vaccine will be offered to this age group.

The vaccine is the second after Pfizer’s to be authorised in the UK for use in older children, though Britain is currently only offering shots to those aged 16 and up, and to vulnerable children aged 12 to 15 who have underlying health conditions such as Down’s syndrome or who live with immunosuppressed adults.

READ MORE

That puts the UK at odds with many of its closest neighbours in Europe and the US, which have offered Covid-19 shots to all adolescents ahead of the new school year.

The UK’s decision not to roll out vaccines to healthy children over 12 was based partly on some rare side effects seen particularly in male teenagers.

The conditions myocarditis and pericarditis – inflammation of the heart muscle and its surrounding membrane – were linked to the mRNA vaccines earlier this year, leading the UK to conclude that the benefits do not yet outweigh the risks.

“We have in place a comprehensive safety surveillance strategy for monitoring the safety of all UK-approved Covid-19 vaccines, and this surveillance will include the 12- to 17-year age group,” June Raine, chief executive officer of the MHRA, said on Tuesday. – Bloomberg

Business Today

Business Today

Get the latest business news and commentary from our expert business team in your inbox every weekday morning